Synbody Biotechnology, Inc., a start-up biotechnology company received it's first seed funding of $750,000. According to SEC filings, only one investor participated in the offering of convertible debt.

Synbody Biotechnology (SBI) is a start-up biotechnology company based on a powerful synthetic antibody, or "Synbody," technology recently discovered at Arizona State University. Synbodies revolutionize the field of high affinity, high specificity therapeutic agents by creating antibody-like function from small purely synthetic peptides. It is SBI's mission to leverage the Synbody technology to create a pipeline of superior human therapeutics across multiple therapeutic areas. SBI seeks to realize the opportunity for synbodies as human therapeutics through a combined strategy comprising corporate partnerships, out-licensing agreements and in-house development.